

Primary Care Consultation Request Initiation of Hepatitis C Treatment in Victoria

Alfred Hospital Liver Clinic (Gastroenterology)	Fax: (03) 9076 2194
Alfred Hospital Infectious Diseases	Fax: (03) 9076 6528
Austin Health Liver Clinic	Fax: (03) 9496 2097
Box Hill Hospital Liver and Hepatitis Clinics	Fax: (03) 9895 4852
St Vincent's Hospital Melbourne Liver & Hepatitis Clinic	Fax: (03) 9231 3596
The Royal Melbourne Hospital Liver Clinic	Fax: (03) 9342 7848
Victorian Infectious Diseases Service – Infectious Hepatitis Clinic	Fax: (03) 9342 7277
Western Health Hepatitis Clinic	Fax: (03) 8345 7217

FOR ATTENTION OF: Dr	Date

Please note this form is not a referral for a patient appointment.

Referring Practitioner						
Note: General practitioners and nurs	se practition	ers are elig	gible to prescribe hep	atitis C treatmen	t under the PBS	
Name Suburb				Postcode		
Phone	/ \			Fax		
Mobile phone	()			ГdХ		
Email address						
Patient						
Name						
Date of birth						
Postcode						
Hepatitis C History			Intercurrent Cond	ditions		
Data of homotitic C (LICV) diagram	.:		Diabetes	[□ Yes □ No	
Date of hepatitis C (HCV) diagnos	SIS:		Obesity		□ Yes □ No	
	□ Na		Hepatitis B (HBV	·)*	□ Yes □ No	
Known cirrhosis*	s 🗆 No		HIV*		□ Yes □ No	
*Patients with cirrhosis, or HBV/HIV	coinfection	with	Alcohol > 4 standard			
HCV should be referred to a specialist.		drinks/day (> 40	g/day)			
		Discussion about contraception				
Prior Antiviral Treatment			Current Medicati	ons		
Has patient previously received a antiviral treatment? (please add below)	•	□Yes □No	(Prescription, herbal, ove	er the counter, recred	ational)	
Has prior treatment included ora	l antiviral	\square Yes				
therapy?		\square No				
Prior treatment:						
I have checked for potential						
drug-drug interactions with curr	ent	☐ Yes	1 http://www.b	al m m. i m. k. m		
medications†			† http://www.hep-		.org this site showing you have	
		_ 110	checked drug-drug		tins site showing you have	
			chica arab arab			



Primary Care Consultation Request Initiation of Hepatitis C Treatment in Victoria

Laboratory Results (or attach copy of results)					
Test	Date	Result	Test	Date	Result
HCV genotype			Creatinine		
HCV RNA level			eGFR		
ALT			Haemoglobin		
AST			Platelet count		
Bilirubin			INR		
Albumin			HBsAg		
Liver Fibrosis Assessment**					
Test	Date	Result			
FibroScan					
Other (eg. APRI)					
APRI: http://www.hepatitisc.uw.edu/page/clinical-calculators/apri					
** People with liver stiffness on FibroScan of ≥ 12.5 kPa, or an APRI score ≥ 1.0 may have cirrhosis and should be referred to a specialist.					

Treatment Choice#

I plan to prescribe (please select/tick one):

· prairies processes (processes and area array)			
Regimen	Durat	Genotypes	
Sofosbuvir + Velpatasvir	12 week	1, 2, 3, 4, 5, 6	
Glecaprevir + Pibrentasvir	8 weeks □ 12 weeks □ No cirrhosis Cirrhosis		1, 2, 3, 4, 5, 6
Elbasvir + Grazoprevir	12 week	1 or 4	
Sofosbuvir + Ledipasvir	8 weeks □ No cirrhosis, treatment-naive	12 weeks □	1

See Australian Recommendations for the Management of Hepatitis C Virus Infection: A Consensus Statement (September 2018) (http://www.gesa.org.au) for all regimens, and for monitoring recommendations.

Patients must be tested for HCV RNA at least 12 weeks after completing treatment to determine outcome. Please notify the specialist below of the Week 12 post-treatment result. Patients who relapse after direct-acting antiviral therapy should be referred to a specialist for retreatment.

Declaration by General Practitioner/Nurse Practitioner

I declare all of the information provided above is true and correct.

Signature:	
Name:	
Date:	

Approval by Specialist Experienced in the Treatment of HCV

I agree with the decision to treat this person based on the information provided above.

Signature:		
Name:		
Date:		
Once completed, please return both pages by email:		
or fax: ()		

^{*}Multiple regimens are available for the treatment of chronic HCV. Factors to consider include HCV genotype, cirrhosis status, prior interferon treatment, viral load, potential drug—drug interactions and comorbidities.